Analgesic Ear Drops for Children With Acute Otitis Media

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

29 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-06

Study Completion Date

2024-01-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial aims to investigate whether analgesic ear drops added to usual care provide superior ear pain relief over usual care alone in children presenting to primary care with AOM. Children will be randomly allocated (ratio 1:1) to either 1) lidocaine hydrochloride 5mg/g ear drops (Otalgan) 1-2 drops up to six times daily for a maximum of 7 days in addition to usual care (oral analgesics, with/without antibiotics) or 2) usual care. Parents will complete a symptom diary for 4 weeks as well as generic and disease-specific quality of life questionnaires at baseline and 4 weeks. The primary outcome is the parent-reported ear pain score (0-10) over the first 3 days.

NOTE:

At the time of publication of the study protocol paper, the investigators were unable to make any amendments to the trial registration record in the Netherlands Trial Register (NTR) (NL9500; date of registration: 28 May 2021). The addition of a data sharing plan was required to adhere to the International Committee of Medical Journal Editors (ICMJE) guidelines. The investigators therefore re-registered the trial in ClinicalTrials.gov. This second registration is for modification purposes only and the NTR record (NL9500) should be regarded as the primary trial registration.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Four Arm Safety & Efficacy With Antipyrine and Benzocaine Otic Solution in Children With Acute Otitis Media

NCT02037893

Acute Otitis Media

COMPLETED PHASE2

Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects

NCT01206907

Chronic Pain

WITHDRAWN PHASE3

A Pilot Study of Intranasal Lidocaine in Acute Management of Pediatric Migraine

NCT03806595

Migraine in Children Posttraumatic Headache

COMPLETED PHASE1

Non-opioids for Analgesia After Adenotonsillectomy in Children

NCT03618823

Adenotonsillectomy Post-operative Analgesia Opioid Use

TERMINATED PHASE1/PHASE2

Non-Steroidal or Opioid Analgesia Use for Children With Musculoskeletal Injuries

NCT03767933

Musculoskeletal Injury

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Otitis Media Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

pragmatic, two arm, individually randomised, open, superiority trial

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lidocaine ear drops with usual care

usual care: oral analgesic with/without antibiotics

Group Type EXPERIMENTAL

lidocaine hydrochloride 5mg/g

Intervention Type DRUG

1-2 drops up to six times daily for a maximum of 7 days

usual care

usual care: oral analgesic with/without antibiotics

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

lidocaine hydrochloride 5mg/g

1-2 drops up to six times daily for a maximum of 7 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Otalgan

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 1 to 6 years
* Parent-reported ear pain in 24 hours prior to enrolment
* GP-diagnosis of (uni- or bilateral) AOM

Exclusion Criteria

* with (suspected) tympanic membrane perforation or ventilation tubes
* with ear wax obscuring visualisation of the tympanic membrane
* who are systemically very unwell or require hospital admission (e.g. child has signs and symptoms of serious illness and/or complications such as mastoiditis/meningitis)
* who are at high risk of serious complications including children with known immunodeficiency other than partial IgA or IgG2 deficiencies, craniofacial malformation including cleft palate, Down syndrome and previous ear surgery (with the exception of ventilation tubes in the past)
* who have a known allergy or sensitivity to study medication or similar substances (e.g. other amide-type anaesthetics: bupivacaine, mepivacaine, prilocaine, etc)
* who have taken part in any research involving medicines within the last 90 days, or any other AOM-related research within the last 30 days
* who suffer from chronic recurrent pain of another origin than the ear
* who have participated in this trial during prior AOM episode

Minimum Eligible Age

1 Year

Maximum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No